NASD · Healthcare · Biotechnology · Australia
Propanc Biopharma Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Propanc Biopharma is a biopharmaceutical company developing an intravenous proenzyme therapy to address cancer stem cells in patients with pancreatic, ovarian, and colorectal cancers. Its lead candidate, PRP, combines pancreatic proenzymes intended to induce cell differentiation and inhibit tumor growth and spread. The company is preparing clinical trials and collaborating with universities on drug discovery research.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Propanc Biopharma Inc stock.
Not valued: We cannot value this company yet.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on PPCB yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.